NCT07529613 2026-04-14
T-DXd_HER2Low
National Cancer Center Hospital East
Phase 1/2 Completed
Clinical Trials
21 trialsNCT06346197 2026-04-08
CIME
Centre Leon Berard
Phase 3 Recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05187182 2026-03-18
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT05802056 2025-12-19
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
Phase 1 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT03453164 2024-09-19
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Fukushima Medical University
Phase 1/2 Completed
NCT03172416 2024-05-29
PIPAC
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT06196554 2024-01-09
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT05535569 2022-09-10
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
Yonsei University
Phase 1/2 Completed
NCT03409848 2022-05-18
INTEGA
AIO-Studien-gGmbH
Phase 2 Completed
NCT04782791 2022-01-11
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT04503967 2020-08-07
OASIS
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03511222 2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed
NCT03784040 2019-04-08
da VINci
National University Hospital, Singapore
Phase 1 Unknown